中国低剂量阿司匹林预防子痫前期(APPEC研究):多中心随机对照试验方案
本研究为中国11省13家三级医院开展的多中心开放标签随机对照试验方案,计划纳入1000例子痫前期高危孕妇,随机分为对照组和干预组。干预组自妊娠12-20周起每晚服用低剂量阿司匹林100 mg/d至妊娠34周,主要结局为子痫前期发生率。这是中国人群首个且最大规模评估低剂量阿司匹林预防子痫前期的多中心随机对照试验。
要点
- 中国高危孕妇中评估低剂量阿司匹林预防子痫前期的大型多中心随机对照试验
- 干预方案为每晚100 mg/d,自妊娠12-20周开始至妊娠34周
- 主要结局为子痫前期发生率,同时收集生物样本和母儿结局
核心结论
- 该研究旨在评估低剂量阿司匹林对中国子痫前期高危孕妇的预防效果,结果可能影响中国产前保健建议。
研究设计与样本
- 开放标签、多中心随机对照试验,在中国11个省份的13家三级医院开展。
- 计划纳入1000例子痫前期高危孕妇,随机分为对照组(n=500)和干预组(n=500)。
关键数值与推荐
- 高危因素包括:子痫前期病史、慢性高血压、1型或2型糖尿病、高龄、肥胖、子痫前期家族史或初产。
- 干预组接受低剂量阿司匹林100 mg/d,每晚服用,自妊娠12-20周开始至妊娠34周。
- 主要结局为子痫前期发生率;次要结局包括母儿结局和母体生物标志物水平。
临床怎么用
- 针对中国子痫前期高危孕妇,可考虑自妊娠12-20周起每晚服用低剂量阿司匹林100 mg/d至妊娠34周,但需等待试验结果确认。
局限性
- 本文件为研究方案,尚未报告试验结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Low-dose aspirin (LDA) has been proposed as a safe and inexpensive prophylactic agent. Studies in European/Western populations have shown promising results indicating that LDA can reduce the occurrence of pre-eclampsia (PE) in women with identifiable risk factors. However, few controlled trials, particularly large randomized controlled trials, have been performed in Asian populations. The aim of this project is to evaluate the effect of LDA for PE prevention on high-risk pregnant women in China, where PE is highly prevalent and the LDA supply status is commonly suboptimal. METHODS/DESIGN: An open-label, multicentre randomized controlled trial is being conducted at 13 tertiary hospitals in 11 provinces in China. A total of 1000 eligible women with high-risk factors for developing PE according to their medical histories are being randomized into two groups: a control group (n = 500) and an intervention group (n = 500). Women with high-risk factors, such as a history of PE, chronic hypertension, type 1 or 2 diabetes, advanced maternal age, obesity, family history of PE or nulliparity are eligible. The control group is advised to undergo routine examinations, whereas the intervention group undergoes the routine examinations and receives LDA. LDA (100 mg/d) should be prescribed at night, initiating from early pregnancy (12-20 weeks of gestation) and lasting until 34 weeks of gestation. Demographic data and clinical endpoint outcomes, as well as biological samples (e.g., maternal blood, cord blood, amniotic fluid and placental samples), will be collected. The primary outcome is the occurrence of PE, and the secondary outcomes include maternal and neonatal outcomes and maternal biomarker levels. DISCUSSION: This is the first and largest multicentre randomized controlled trial to assess the effect of LDA in preventing PE in a Chinese population. The results will potentially influence the prenatal care recommendations in China regarding intervention with LDA for PE. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02797249 . Registered on 7 June 2016.
引用
- Lin L, Zhu Y, Li B, et al. Low-dose aspirin in the prevention of pre-eclampsia in China (APPEC study): protocol for a multicentre randomized controlled trial. Trials. 2018. PMID: 30400937. doi:10.1186/s13063-018-2970-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。